

# Sarah L Anderson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6425047/publications.pdf>

Version: 2024-02-01

37  
papers

826  
citations

516710

16  
h-index

501196

28  
g-index

37  
all docs

37  
docs citations

37  
times ranked

1080  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quetiapine for insomnia: A review of the literature. American Journal of Health-System Pharmacy, 2014, 71, 394-402.	1.0	97
2	Association of Pancreatitis with Glucagon-Like Peptide-1 Agonist Use. Annals of Pharmacotherapy, 2010, 44, 904-909.	1.9	76
3	Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population. Pharmacotherapy, 2016, 36, 505-510.	2.6	71
4	Histamine-1 receptor antagonism for treatment of insomnia. Journal of the American Pharmacists Association: JAPhA, 2012, 52, e210-e219.	1.5	65
5	Suvorexant in insomnia: efficacy, safety and place in therapy. Therapeutic Advances in Drug Safety, 2015, 6, 189-195.	2.4	64
6	Novel class of medications, orexin receptor antagonists, in the treatment of insomnia &ndash; critical appraisal of suvorexant. Nature and Science of Sleep, 2016, Volume 8, 239-247.	2.7	43
7	Dapagliflozin efficacy and safety: a perspective review. Therapeutic Advances in Drug Safety, 2014, 5, 242-254.	2.4	42
8	A Review of the Role of the Pharmacist in Heart Failure Transition of Care. Advances in Therapy, 2018, 35, 311-323.	2.9	41
9	Oral semaglutide in type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107520.	2.3	39
10	Basal Insulin Use With GLP-1 Receptor Agonists. Diabetes Spectrum, 2016, 29, 152-160.	1.0	34
11	Dapagliflozin for the Treatment of Type 2 Diabetes. Annals of Pharmacotherapy, 2012, 46, 590-598.	1.9	29
12	Determining predictors of response to exenatide in type 2 diabetes. Journal of the American Pharmacists Association: JAPhA, 2012, 52, 466-471.	1.5	26
13	Implementation of a Clinical Pharmacy Specialist-Managed Telephonic Hospital Discharge Follow-Up Program in a Patient-Centered Medical Home. Population Health Management, 2013, 16, 235-241.	1.7	25
14	Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness. Therapeutic Advances in Chronic Disease, 2016, 7, 4-17.	2.5	24
15	Role of clinical pharmacists and pharmacy support personnel in transitions of care. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 532-545.	1.0	24
16	Bempedoic acid for the treatment of dyslipidemia. Drugs in Context, 2020, 9, 1-9.	2.2	21
17	Once-weekly albiglutide in the management of type 2 diabetes: patient considerations. Patient Preference and Adherence, 2014, 8, 789.	1.8	16
18	Prevalence of and Factors That Influence Board Certification Among Pharmacy Practice Faculty at United States Colleges and Schools of Pharmacy. Pharmacotherapy, 2013, 33, 105-111.	2.6	13

#	ARTICLE	IF	CITATIONS
19	Current and future state of quality metrics and performance indicators in comprehensive medication management for ambulatory care pharmacy practice. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 390-405.	1.0	12
20	Intentional Brodifacoum Ingestion. American Journal of Medicine, 2017, 130, e27-e28.	1.5	10
21	Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment. Drugs in Context, 2018, 7, 1-7.	2.2	10
22	Antihyperglycemic Medications and Cardiovascular Risk Reduction. European Endocrinology, 2017, 13, 86.	1.5	9
23	Evaluation of a Pharmacist-Led Intervention to Improve Statin Use in Persons with Diabetes. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 910-917.	0.9	7
24	Strategies for successfully navigating the pharmacy residency interview process. American Journal of Health-System Pharmacy, 2015, 72, S33-S35.	1.0	6
25	Switching basal insulins in type 2 diabetes: practical recommendations for health care providers. Postgraduate Medicine, 2018, 130, 229-238.	2.0	6
26	Implementation of a Pharmacist-Led Diabetes Management Protocol. American Health and Drug Benefits, 2019, 12, 14-20.	0.5	4
27	Evaluation of Aspirin Use in Patients With Diabetes Receiving Care in Community Health. Annals of Pharmacotherapy, 2015, 49, 170-177.	1.9	3
28	Direct Oral Anticoagulant Use in Valvular Heart Disease. Clinical Medicine Insights Therapeutics, 2018, 10, 1179559X1775163.	0.4	3
29	Can Direct Oral Anticoagulants Be Used for Stroke Prevention Among Patients with Valvular Atrial Fibrillation?. Current Cardiology Reports, 2019, 21, 118.	2.9	2
30	Characterization of diabetes risk factors in patients prescribed chronic statin therapy. Therapeutic Advances in Chronic Disease, 2014, 5, 206-211.	2.5	1
31	Probable Interaction Between Warfarin and Divalproex Sodium. Journal of Pharmacy Technology, 2014, 30, 8-12.	1.0	1
32	Role of Aldosterone Receptor Antagonists in Heart Failure With Preserved Ejection Fraction. Clinical Medicine Insights Therapeutics, 2018, 10, 1179559X1877135.	0.4	1
33	Retrospective cohort study of statin prescribing for primary prevention among people living with HIV. JRSM Cardiovascular Disease, 2021, 10, 204800402110310.	0.7	1
34	Response to Comment "Evaluation of Aspirin Use for Primary Prevention in Diabetic Patients". Annals of Pharmacotherapy, 2015, 49, 262-263.	1.9	0
35	Characterization of diastolic dysfunction heart failure following an acute hospitalization for heart failure in an urban, underserved population. Therapeutic Advances in Cardiovascular Disease, 2015, 9, 267-274.	2.1	0
36	Characterization of clinical pharmacist and hospitalist collaborative relationships. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 1413-1422.	1.0	0

#	ARTICLE	IF	CITATIONS
37	Drugs in Context Editorial: Review of 2020 and what lies ahead in therapeutic interventions. Drugs in Context, 2021, 10, 1-5.	2.2	0